Advertisement
Advertisement

MGX

MGX logo

Metagenomi Therapeutics, Inc. Common Stock

1.54
USD
Sponsored
-0.04
-2.22%
Jan 30, 11:26 UTC -5
Open

MGX Earnings Reports

Positive Surprise Ratio

MGX beat 6 of 8 last estimates.

75%

Next Report

Date of Next Report
Mar 11, 2026
Estimate for Q4 25 (Revenue/ EPS)
$6.81M
/
-$0.61
Implied change from Q3 25 (Revenue/ EPS)
-21.33%
/
+10.91%
Implied change from Q4 24 (Revenue/ EPS)
-29.15%
/
-3.17%

Metagenomi Therapeutics, Inc. Common Stock earnings per share and revenue

On Nov 11, 2025, MGX reported earnings of -0.55 USD per share (EPS) for Q3 25, beating the estimate of -0.58 USD, resulting in a 6.75% surprise. Revenue reached 8.66 million, compared to an expected 7.47 million, with a 15.85% difference. The market reacted with a -15.45% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 6 analysts forecast an EPS of -0.61 USD, with revenue projected to reach 6.81 million USD, implying an increase of 10.91% EPS, and decrease of -21.33% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Teva Pharmaceutical Industries Limited - ADR
Report Date
Jan 28, 2026 For Q4 25
Estimate
$0.69
Actual
$0.96
Surprise
+38.55%
logo
Dr. Reddy's Laboratories Limited - ADR
Report Date
Jan 21, 2026 For Q3 26
Estimate
$13.86
Actual
$14.65
Surprise
+5.66%
FAQ
For Q3 2025, Metagenomi Therapeutics, Inc. Common Stock reported EPS of -$0.55, beating estimates by 6.75%, and revenue of $8.66M, 15.85% above expectations.
The stock price moved down -15.45%, changed from $2.20 before the earnings release to $1.86 the day after.
The next earning report is scheduled for Mar 11, 2026.
Based on 6 analysts, Metagenomi Therapeutics, Inc. Common Stock is expected to report EPS of -$0.61 and revenue of $6.81M for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement